Rita Paniccia

Rita Paniccia

Auto-generated profile, based on publicly available information

Rita Paniccia

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in JACC
Verified
Journal Article
Closed access
PBPiergiovanni Buonamici
Piergiovanni Buonamici
RMRosella Marcucci
Rosella Marcucci
AMAngela Migliorini
Angela Migliorini
GGGian Franco Gensini
Gian Franco Gensini
ASAlberto Santini
Alberto Santini
DADavid Antoniucci
David Antoniucci

20 January 2009 in Circulation
Verified
Journal Article
Open access
PDF file
RMRosella Marcucci
Rosella Marcucci
AGAnna Maria Gori
Anna Maria Gori
RPRita Paniccia
Rita Paniccia
BGBetti Giusti
Betti Giusti
SVSerafina Valente
Serafina Valente
GGGian Franco Gensini
Gian Franco Gensini
Background— The clinical impact of platelet aggregation assessed by point-of-care assays is unknown. We sought to evaluate whether high residual platelet reactivity (RPR) to ADP during clopidogrel therapy, measured by a point-of-care assay, predicts adverse clinical events in acute coronary syndrome patients undergoing percutaneous coronary intervention. Methods and Results— We used the VerifyNow P2Y12 assay (Accumetrics Inc, San Diego, Calif) to determine RPR to ADP in 683 patients with acute coronary syndrome undergoing dual-antiplatelet therapy who underwent percutaneous coronary intervention with bare-metal or drug-eluting stent implantation. All patients received a single 600-mg clopidogrel loading dose followed by 75 mg of clopidogrel daily and 100 to 325 mg of aspirin daily. The end points of the study at follow-up of 12 months were cardiovascular death, nonfatal myocardial infarction (MI), and target-vessel revascularization. At a 12-month follow-up, we found 51 ischemic events (24 cardiovascular deaths [3.5%], 27 nonfatal MIs [3.9%]) and 40 target-vessel revascularizations (5.8%). By receiver operating characteristic curve (ROC) analysis, the optimal cutoff value in predicting 12-month cardiovascular death and nonfatal MI was P2Y12 reaction unit values ≥240. RPR, defined in the presence of P2Y12 reaction unit values above this cutoff, was found to be a significant and independent predictor of cardiovascular death and nonfatal MI in a model that adjusted for cardiovascular risk factors, renal failure, reduced left ventricular ejection fraction, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent, and use of glycoprotein IIb/IIIa inhibitors (cardiovascular death: hazard ratio 2.55, 95% CI 1.08 to 6.07, P =0.034; nonfatal MI: hazard ratio 3.36, 95% CI 1.49 to 7.58, P =0.004). No significant association was found between high RPR and the risk of target-vessel revascularization. Conclusions— RPR to ADP with clopidogrel therapy, measured by the point-of-care assay VerifyNow P2Y12, is able to detect acute coronary syndrome patients at risk of 12-month cardiovascular death and nonfatal MI. The optimal cutoff value was identified as being 240 P2Y12 reaction units.

1 February 2015 in Vascular Health and Risk Management
Verified
Journal Article
Open access
RPRita Paniccia
Rita Paniccia
RPRaffaella Priora
Raffaella Priora
ALAgatina Alessandrello Liotta
Agatina Alessandrello Liotta
RARosanna Abbate
Rosanna Abbate
In physiological hemostasis a prompt recruitment of platelets on the vessel damage prevents the bleeding by the rapid formation of a platelet plug. Qualitative and/or quantitative platelet defects promote bleeding, whereas the high residual reactivity of platelets in patients on antiplatelet therapies moves forward thromboembolic complications. The biochemical mechanisms of the different phases of platelet activation – adhesion, shape change, release reaction, and aggregation – have been well delineated, whereas their complete translation into laboratory assays has not been so fulfilled. Laboratory tests of platelet function, such as bleeding time, light transmission platelet aggregation, lumiaggregometry, impedance aggregometry on whole blood, and platelet activation investigated by flow cytometry, are traditionally utilized for diagnosing hemostatic disorders and managing patients with platelet and hemostatic defects, but their use is still limited to specialized laboratories. To date, a point-of-care testing (POCT) dedicated to platelet function, using pertinent devices much simpler to use, has now become available (ie, PFA-100, VerifyNow System, Multiplate Electrode Aggregometry [MEA]). POCT includes new methodologies which may be used in critical clinical settings and also in general laboratories because they are rapid and easy to use, employing whole blood without the necessity of sample processing. Actually, these different platelet methodologies for the evaluation of inherited and acquired bleeding disorders and/or for monitoring antiplatelet therapies are spreading and the study of platelet function is strengthening. In this review, well-tried and innovative platelet function tests and their methodological features and clinical applications are considered.

1 December 2007 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
BGBetti Giusti
Betti Giusti
AGAnna Maria Gori
Anna Maria Gori
RMRosella Marcucci
Rosella Marcucci
CSClaudia Saracini
Claudia Saracini
ISIlaria Sestini
Ilaria Sestini
GGGian Franco Gensini
Gian Franco Gensini
Objectives The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment. Background Residual platelet reactivity (RPR) phenomenon on antiplatelet therapy requires clarification. P2Y12 T744C, CYP3A4 IVS10+12G/A and, in healthy individuals only, CYP2C19*2 polymorphisms have been investigated; however, the influence on platelet reactivity in a large population of high-risk vascular patients on dual antiplatelet treatment has not yet been elucidated. Methods A total of 1419 acute coronary syndrome patients on dual antiplatelet treatment were studied. Platelet function was evaluated by platelet-rich plasma aggregation. Electronic nanochips and restriction-fragment length polymorphism were used for analysis of polymorphisms. Results Only CYP2C19*2, out of the three investigated polymorphisms, is associated with higher platelet reactivity. Carriers of the *2 allele had significantly higher platelet aggregation values after arachidonic acid (AA; P=0.043), 2 μmol/l adenosine 5′ diphosphate (ADP; P<0.0001) and 10 μmol/l ADP (P=0.001) stimuli. The genotype distribution of CYP2C19*2 polymorphism significantly differed between patients with and without RPR, as evaluated by 10-μmol/l ADP-induced platelet aggregation (P=0.002) and by AA-induced platelet aggregation (P=0.045). At the multivariate linear regression analysis, the CYP2C19*2 polymorphism remained a significant and independent risk factor for dual antiplatelet treatment variability. Conclusions This study demonstrates, for the first time, that the *2 CYP2C19 allele is associated with higher platelet aggregability and RPR in high-risk vascular patients on dual antiplatelet treatment. These findings can have a significant impact on the future design of pharmacogenetic antiaggregant strategies for high-risk vascular patients on dual antiplatelet treatment.

1 March 2009 in The American Journal of Cardiology
Verified
Journal Article
Closed access
BGBetti Giusti
Betti Giusti
AGAnna Maria Gori
Anna Maria Gori
RMRosella Marcucci
Rosella Marcucci
CSClaudia Saracini
Claudia Saracini
ISIlaria Sestini
Ilaria Sestini
GGGian Franco Gensini
Gian Franco Gensini

1 August 2008 in JACC
Verified
Journal Article
Closed access
AGAnna Maria Gori
Anna Maria Gori
RMRosella Marcucci
Rosella Marcucci
AMAngela Migliorini
Angela Migliorini
RVRenato Valenti
Renato Valenti
GMGuia Moschi
Guia Moschi
DADavid Antoniucci
David Antoniucci